AstraZeneca/BTG abandon CytoFab for sepsis as it fails in Ph IIb
Anglo-Swedish drug major AstraZeneca (LSE: AZN) has decided to halt any further development of AZD9773 (CytoFab) for the treatment of severe sepsis and/or septic shock, and will hand the asset back to partner BTG (LSE: BTG) following the drugs failure in a Phase IIb clinical trial. The news saw AstraZeneca’s shares fall 2.2% to £30.15 and BTG’s dropping as much a 10% before closing the day up 1.5% at £3.43.
Top-line data from a global double-blind Phase IIb study comparing the efficacy and safety of two doses of AZD9773 with placebo in patients with severe sepsis and/or septic shock, conducted by AstraZeneca did not show any significant improvements versus placebo in respect of the primary endpoint, ventilator-free days, or secondary endpoints including mortality.
High risk gamble that failed
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze